AstraZeneca expects only limited impact from potential U.S. tariffs on pharmaceutical imports, the drugmaker said on Tuesday, ...

CEO Pascal Soriot is not overly concerned about the threat of tariffs by the Trump administration on pharmaceuticals and said ...

AstraZeneca Plc’s Chief Executive Officer Pascal Soriot warned that trade tariffs are not the best way to manage ...

The chief executive of the Cambridge-headquartered pharmaceutical giant AstraZeneca has urged the European Union to allow the ...

Pascal Soriot (pictured) said innovation in pharma 'has mostly been funded by the US' as he doubled down on plans to grow the ...

Discover AstraZeneca's Q1 2025 performance with 10% revenue growth, innovative medicines, and bold 2030 goals.

AstraZeneca CEO Pascal Soriot joins Morning Brief to discuss the outlook for the company and outlines AstraZeneca's plans to expand manufacturing and R&D operations in the US To watch more expert ...

Sir Pascal Soriot, AstraZeneca’s chief executive, said governments could “decide to not spend” on new medicines, but “then the jobs and the investments will go elsewhere”. He said ...

AstraZeneca Plc’s Chief Executive Officer Pascal Soriot warned that trade tariffs are not the best way to manage pharmaceuticals and that drugmakers are calling for no additional US levies on ...

Sir Pascal Soriot is usually several steps ahead of the game, so always worth listening to. His latest red flag is that Europe is falling behind in healthcare innovation and manufacturing ...

AstraZeneca has come up short in another phase 3 trial of the AKT inhibitor Truqap, raising more questions about the ...